BJMO - volume 10, issue 8, december 2016
T. Vermassen PhD, S. Rottey MD, PhD
The central theme of ESMO 2016 was ‘From disease treatment to patient care’, and the congress aimed at further integrating clinical research with patient needs. This report will highlight 9 key studies concerning renal cell carcinoma and metastatic prostate cancer, some of which were presented during one of the presidential sessions of the meeting.
(BELG J MED ONCOL 2016;10(8):295–300)
Read moreBJMO - volume 10, issue 8, december 2016
J. Kerger MD
ESMO 2016 not only reflected the increasing interest in oncology by attracting close to 20.000 participants, but also featured the presentation of several important abstracts that may lead to changes in the daily clinical management of gynaecological cancers. This was especially the case for ovarian carcinomas.
(BELG J MED ONCOL 2016;10(8):301–07)
Read moreBJMO - volume 10, issue 8, december 2016
H. Wildiers MD, PhD, Tom Feys MBA, MSc
(BELG J MED ONCOL 2016;10(8):308–13)
Read moreBJMO - volume 10, issue 8, december 2016
V. Kruse MD, PhD, L. Brochez MD, PhD
Although immunotherapy for melanoma caught a lot of interest at this year ESMO congress, some interesting new data on targeted therapies were presented as well. We have selected 10 abstracts, which, to our opinion, deserve some extra attention.
(BELG J MED ONCOL 2016;10(8):314–18)
Read moreBJMO - volume 10, issue 8, december 2016
Tom Feys MBA, MSc
The main focus of attention at ESMO 2016 in the filed of lung cancer was again the use of checkpoint inhibitors. Two studies evaluating a PD1-inhibitor in the first line treatment of metastatic non-small-cell lung cancer (NSCLC) were presented with conflicting results. In addition to this, positive results with the PD-L1 inhibitor atezolizumab were presented together with promising findings with neo-adjuvant nivolumab in the management of early stage NSCLC. ESMO 2016 also featured important data on (new) targeted agents. In this light, the results of the ASCEND-5 study, assessing the efficacy and safety of ceritinib in patients with advanced ALK+ NSCLC who progressed on prior crizotinib and chemotherapy, were presented. Also the final results of the phase III LUX-Lung 7 study, and of the IMPRESS trial will be discussed in this summary. Finally, data were presented with the MEK inhibitor selumetinib in advanced NSCLC.
(BELG J MED ONCOL 2016;10(8):319–24)
Read moreBJMO - volume 10, issue 8, december 2016
P. Specenier MD, PhD
(BELG J MED ONCOL 2016;10(8):327–30)
Read moreBJMO - volume 10, issue 6, september 2016
H. Van Poppel MD, PhD
The 31st European Association of Urology Annual Congress took place in March 2016 in Munich. In prostate cancer the early use of chemotherapy in addition to androgen deprivation therapy in men with primary metastatic disease is a clinical practice changing concept that needs implementation through collaboration between urologists and medical oncologists.
The role of MRI and fusion biopsies in early detection, diagnosis and active surveillance strategies is becoming more and more important. In bladder cancer, non-urothelial tumour types got a lot of attention and specific treatment strategies were presented. Furthermore, immunological treatment came forward to perhaps replace chemotherapy in the management of advanced urothelial bladder cancer.
(BELG J MED ONCOL 2016;10(6):228–231)
Read more
Top
